3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Conditions
Prostatic Neoplasms
6
Neuroendocrine Tumors
5
Neoplasms
4
Breast Neoplasms
4
Esophageal Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Smoking Cessation
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Pulmonary Nodules
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Large B-cell Lymphoma
1
Hypoxia
1
Hodgkin Disease
1
Hepatic Malignancies
1
Interventions
Dexamethasone
5
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Blood Specimen Collection
4
Surveys and Questionnaires
3
Prednisone
3
Melphalan
3
Lenalidomide
3
Biopsy, Fine-Needle
3
fluciclovine F-18
2
carfilzomib
2
Positron-Emission Tomography
2
Mammography
2
Injections
2
Immunohistochemistry
2
Gemcitabine
2
Cytarabine
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
weifuchun
1
vistusertib
1
venetoclax
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
phosphoribosylformylglycinamidine synthetase
1
pembrolizumab
1
ofatumumab
1
obinutuzumab
1
lortalamine
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Disease
×
Positron Emission Tomography Computed Tomography
×
Clear all
NCT03429387
2022-05-17
PIPPIN
Peter MacCallum Cancer Centre, Australia
Phase NA
Completed
147 enrolled